Breast cancer

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 28, 2024
Cream, Dysmenorrhea, Patient, History, Bacteria, G&A, Vaginal discharge, IND, Bayer, Human development, Investment, Diclofenac, NSAID, Menstruation, Research, Hormone, Bacterial vaginosis, P-value, Webcast, SAN, NIH, Trial of the century, Pleasure, Woman, Breast cancer, Safety, Pharmacokinetics, Food, Development, Menopause, Nonsteroidal anti-inflammatory drug, HR, ARPA, VVA, Tamoxifen, FDA, Attention, CRADA, Female, Dyspareunia, Ecosystem, NICHD, Bangladesh Technical Education Board

SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.

Key Points: 
  • In addition, we are excited about the increased attention that women’s health has received more broadly,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience.
  • In December 2023, Daré announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1.
  • Financial Highlights for the Year Ended December 31, 2023 and 2024 Projections
    Cash and cash equivalents: $10.5 million at December 31, 2023.
  • Daré will host a conference call and live webcast today, March 28, 2024, at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2023 and to provide a company update.

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, Fulvestrant, Prostate cancer, Entrepreneurship, Disease, Webcast, Patient, Sale, G&A, CELC, Investment, GAAP, Breast cancer, PIK3CA, PAM, Pharmaceutical industry

Unless otherwise stated, all comparisons are for the fourth quarter and full year ended December 31, 2023, compared to the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Unless otherwise stated, all comparisons are for the fourth quarter and full year ended December 31, 2023, compared to the fourth quarter and full year ended December 31, 2022.
  • Total operating expenses were $19.7 million for the fourth quarter of 2023, compared to $11.6 million for the fourth quarter of 2022.
  • Net cash used in operating activities for the fourth quarter of 2023 was $18.5 million, compared to $9.5 million for the fourth quarter of 2022.
  • ET today to discuss the fourth quarter and full year 2023 financial results and provide a corporate update.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

SimBioSys Launches TumorSight Plan, A Pioneering Clinical Decision Support for Early-Stage Breast Cancer

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Consumer, Other Health, Radiology, Surgery, Artificial Intelligence, Oncology, Medical Devices, Software, General Health, Health Technology, Women, Breast cancer, MRI, Breast Cancer Care, Mastectomy, Science, Patient, Artificial intelligence, 3D, Cancer, Surgeon, Woman, Risk assessment, CMO, Simbiosys, FDA, Medicine, Medical imaging

Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.

Key Points: 
  • Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.
  • TumorSight Plan is powered by the FDA-cleared TumorSight Viz , an innovative 3D visualization solution to support the rapidly increasing use of MRI imaging in Breast Cancer.
  • SimBioSys’ TumorSight suite is a huge breakthrough in our capacity to utilize AI to calibrate a balance between decision standardization and individualized medicine.
  • TumorSight Plan gives the breast cancer surgeon a platform and opportunity to enable more analytical patient-centric decision making which should lead to higher percentage of women undergoing breast conservation surgery.”

CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Health, Technology, Hospitals, Genetics, Software, Genomics, Organization, Genetic testing, Risk, Patient, Mortality, AI, Risk assessment, Moonshot, Breast cancer, Multimedia, Pharmaceutical industry

CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.

Key Points: 
  • CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.
  • The profiles of the honorees are featured in the April 8, 2024 issue of MH magazine and online at ModernHealthcare.com/Innovator-Awards .
  • “The role of innovation has always been paramount in healthcare, and our 2024 honorees as top Innovators are driving real change in the industry,” said Mary Ellen Podmolik, editor in chief of Modern Healthcare.
  • She has driven adoption of the platform across 225 diverse clinical locations and specialties to make a direct patient impact.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Oncology, Medical Devices, Health, Genetics, Clinical Trials, Biotechnology, Survival, Patient, RNA, DNA, Cancer, University, Biology, Woman, AACR, Catalog, Breast cancer, MRD, DCIS, Blood, Medical imaging

Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.

Key Points: 
  • Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting.
  • In addition, the study showed the platform’s unique capability to distinguish low grade, less aggressive DCIS from invasive breast cancer with 87% sensitivity, at 90% specificity using a standard blood sample.
  • These results suggest the potential for Exai's platform to aid in tailoring adjuvant treatment for individual triple negative breast cancer patients.
  • oncRNAs are actively secreted from living cancer cells and are stable and abundant in the blood of cancer patients.

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024

Retrieved on: 
Sunday, April 7, 2024
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, SOC, Melanoma Research, Oncogene, RNA-binding protein, Patient, SVP, Neoplasm, RNA, Cancer, Messenger, Melanoma, Lung cancer, Society, IND, Immortalised cell line, AACR, Breast cancer, RBP, Therapy, Translational medicine, Vaccine

These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .

Key Points: 
  • These data build on presentations at last year’s Society for Melanoma Research and San Antonio Breast Cancer Symposium .
  • eIF4E is a main regulator and rate limiting factor for protein synthesis and is elevated in many kinds of tumors.
  • Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC.
  • “The ability to target RNA-binding proteins that regulate oncogenes is a powerful modality with the potential to address cancer indications with high unmet need.

MOLLI Surgical Unveils OncoPen, a New Surgical Tool for Empowering Precision and Confidence in the Operating Room

Retrieved on: 
Tuesday, April 9, 2024
Prevalence, Patient, Cancer, Surgeon, Neoplasm, Breast cancer, Surgical oncology, Health, Birth control

DEERFIELD, Ill., April 9, 2024 /PRNewswire/ -- MOLLI Surgical continues to push the boundaries of surgical care with the launch of OncoPen™, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer. The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System, offering sophisticated tools for precisely targeting and removing cancerous lesions.

Key Points: 
  • The sleek, pen-like wand seamlessly integrates with the award-winning MOLLI® 2 System , offering sophisticated tools for precisely targeting and removing cancerous lesions.
  • Unlike traditional techniques, it eliminates the need for wires, providing increased scheduling flexibility for surgeons and a better patient experience.
  • During surgery, the surgeon is directed using real-time 3D guidance on the MOLLI® Tablet to the precise location of the lesion.
  • "At MOLLI Surgical, our relentless focus is on the patient, placing their well-being at the core of all our efforts," said Ananth Ravi, President and CEO of MOLLI Surgical.

OOFOS Surpasses $4 Million Milestone in Project Pink Donations

Retrieved on: 
Tuesday, April 9, 2024
Ali, Breast cancer, Dana–Farber Cancer Institute, Patient, Research, Pink, Boston Marathon, The Jimmy Fund, Shoe, Woman, Microsoft Kin, MPH, PMC, Division, Nursing, Christine St-Pierre, Pharmaceutical industry

BRAINTREE, Mass., April 9, 2024 /PRNewswire/ -- OOFOS, the global leader in Active Recovery footwear, today proudly announces a monumental achievement in their Project Pink initiative, surpassing the extraordinary milestone of $4 million in all-time donations to Dana-Farber Cancer Institute and the Jimmy Fund. Through several fundraising initiatives, OOFOS solidifies its unwavering dedication to breast cancer awareness, research, and patient support.

Key Points: 
  • Since its inception in 2015, Project Pink has been a beacon of support for those battling breast cancer.
  • Since its inception in 2015, Project Pink has been a beacon of support for those battling breast cancer.
  • Through Project Pink, OOFOS donates a portion of all sales made on OOFOS.com to Dana-Farber, ultimately leading to the $4 million.
  • In addition to ongoing contributions through Project Pink, OOFOS has undertaken various impactful campaigns to further contribute to this vital cause.